Zynerba Pharmaceuticals Inc (ZYNE) stock up 18% Tuesday and has gained 21.08% over the last 12 months. The average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives ZYNE stock a score of 75 out of a possible 100.
That score is chiefly influenced by a long-term technical score of 99. ZYNE’s score also includes a short-term technical score of 73. The fundamental score for ZYNE is 53. In addition to the average rating from Wall Street analysts, ZYNE stock has a mean target price of $21.25. This means analysts expect the stock to climb 55.45% over the next 12 months.
What’s Happening with ZYNE Stock Today
Zynerba Pharmaceuticals Inc (ZYNE) stock has risen 18.09% while the S&P 500 has gained 0.49% as of 10:40 AM on Tuesday, Jun 11. ZYNE has gained $2.09 from the previous closing price of $11.58 on volume of 2,673,826 shares. Over the past year the S&P 500 has risen 4.27% while ZYNE has gained 21.08%. ZYNE lost -$2.27 per share in the over the last 12 months.